Immunotherapy plus chemoradiation shows promise in cervical cancer trial
NCT ID NCT03298893
First seen Nov 01, 2025 · Last updated May 22, 2026 · Updated 24 times
Summary
This early-phase study tested whether adding the immunotherapy drug nivolumab to standard chemoradiation is safe for people with locally advanced cervical cancer. Twenty-one adults took part, receiving nivolumab alongside radiation and cisplatin, followed by up to six months of nivolumab alone. The main goal was to check for serious side effects, with a secondary look at how well the cancer responded.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED CERVICAL CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Hopital Européen Georges Pompidou
Paris, 75015, France
-
Institut Curie
Paris, 75005, France
-
Institut Curie Hopital René Huguenin
Saint-Cloud, 9220, France
Conditions
Explore the condition pages connected to this study.